Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease

Vaccine

Volumn 17, Issue 19, 1999, Pages 2377-2383

  Fischer, Marc ^a,b   Carlone, George M ^b   Holst, Johan ^c   Williams, Derrick ^b   Stephens, David S ^d   Perkins, Bradley A ^b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neisseria meningitidis; Serogroup B; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; MENINGOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERICIDAL ACTIVITY; BLOOD GROUP TYPING; DOSE RESPONSE; ERYTHEMA; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; SKIN DEFECT; VACCINATION;

EID: 0033553611     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00036-5     Document Type: Article

References (30)

1. Frasch C.E. Meningococcal vaccines. Cartwright K. Meningococcal disease. 1995;245-283 John Wiley and Sons Ltd.
2. Al'Aldeen A.A., Cartwright K.A. Neisseria meningitidis: vaccines and vaccine candidates. J. Infect. 33:1996;153-157.
3. Lieberman J.M., Chiu S.S., Wong V.K. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA. 275:1996;1499-1503.
4. Lowell G.H. Proteosomes, hydrophobic anchors, ISCOMs and liposomes for improved presentation of peptide and protein vaccines. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 1997;193-206 Marcel Dekker, New York.
5. Einhorn M.S., Weinberg G.A., Anderson E.L., Granoff P.D., Granoff D.M. Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet. 2:1986;299-302.
6. Kayhty H., Ahman H., Ronnberg P.R., Tillikainen R., Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis. 172:1995;1273-1278.
7. Swaminathan B., Matar G.M., Reeves M.W., Graves L.M., Ajello G., Bibb W.F., Helsel L.O., Morales M., Dronavalli H., El-Swify M., DeWitt W., Hunter S.B. Molecular subtyping of Neisseria meningitidis serogroup B: a comparison of five methods. J. Clin. Microbiol. 34:1996;1468-1473.
8. Raymond N.J., Reeves M., Ajello G., Baughman W., Gheesling L.L., Carlone G.C., Wenger J.D., Stephens D.S. Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease. J. Infect. Dis. 176:1997;1277-1284.
9. Maiden M.C.J., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., Zhang Q., Zhou J., Zurth K., Caugant D.A., Feavers I.M., Achtman M., Spratt B.G. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. USA. 95:1998;3140-3145.
10. Pike R.M. Laboratory-associated infections: incidence, fatalities, causes and prevention. Ann. Rev. Microbiol. 33:1979;41-66.
11. Bhatti A.R., DiNinno V.L., Ashton R.E., White L.A. A laboratory-acquired infection with Neisseria meningitidis. J. Infect. 4:1982;247-252.
12. Laboratory-acquired meningococcemia: California and Massachusetts. MMWR. 40:1991;46-55.
13. PHLS Communicable Disease Surveillance Center. Laboratory-acquired meningococcal infection. Communicable Disease Report. 1992;2:39.
14. Guibourdenche M, Darchis JP, Boisivon A, Collatz E, Riou J-Y. Enzyme electrophoresis, sero- and subtyping, and outer membrane protein characterization of two Neisseria meningitidis strains involved in laboratory-acquired infections. J Clin Microbiol 1994;32:a-d.
15. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 46:1997;1-10.
16. Bjune G., Høiby E.A., Grønnesby J.K., Arnesen Ø., Fredriksen J.H., Halstensen A., Holten E., Lindbak A.-K., Nøkleby H., Rosenqvist E., Solberg L.K., Closs O., Eng J., Frøholm L.O., Lystad A., Bakketeig L.S., Hareide B. Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
17. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Høiby E.A., Rosenqvist E., Holst J., Nøkleby H., Sotolongo F., Sierra G., Campa H.C., Carlone G.C., Williams D., Dykes J., Kapczynski D., Tikhomirov E., Wenger J.D., Broome C.V. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:1998;683-691.
18. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GC, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. Immunogenicity of two outer membrane protein serogroup B meningococcal vaccines: a randomized, controlled trial. Submitted for publication.
19. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus IV. Immunogenicity of the group A and group C polysaccharides in human volunteers. J. Exp. Med. 129:1969;1367-1384.
20. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., Martinez M., Arthur J., Underwood P., Silva W., Moran E., Hankins W., Gilly J., Mays J. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 13:1995;821-829.
21. De Moraes J.C., Perkins B.A., Camargo M.C.C., Hidalgo N.T.R., Barbosa H.A., Sacchi C.T., Gral I.M.L., Gattas V.L., Vasconcelos H.D.G., Plikaytis B.D., Wenger J.D., Broome C.V. Protective efficacy of a serogroup B meningococcal vaccine in São Paolo, Brazil. Lancet. 340:1992;1074-1078.
22. Milagres L.G., Ramos S.R., Sacchi C.T., Melles C.E.A., Vieira V.S.D., Sato H., Brito G.S., Moraes J.C., Frasch C.E. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424.
23. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L.O., Lindbak A.-K., Mogster B., Namork E., Rye U., Stabbetorp G., Winsnes R., Aase B., Closs O. Production, characterization, and control of Men B-vaccine 'Folkhelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:1991;67-79.
24. Høiby E.A., Rosenqvist E., Frøholm L.O., Bjune G., Feiring B., Nøkleby H., Rønnild E. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:1991;147-156.
25. Centers for Disease Control and Prevention. Unpublished data.
26. Rosenqvist E., Høiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., Rønnild E., Bjune G., Nøkleby H. Human antibody responsees to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:1995;4642-4652.
27. Zollinger W.D. New and improved vaccines against meningococcal disease. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 1997;469-488 Marcel Dekker, New York.
28. Rosenqvist E., Høiby E.A., Bjune G., Aase A., Halstensen A., Lehmann A.K., Paulssen J., Holst J., Michaelsen T.E., Nøkleby H., Frøholm L.O., Closs O. Effect of aluminum hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Brown F., Haaheim L.R. Modulation of the immune response to vaccine antigens. Dev Biol Stand. 92:1998;323-333 Karger, Basel.
29. Collier L.H., Polakoff S., Mortimer J. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines. Lancet. 1:1979;1364-1368.
30. Blumberg D.A., Mink C.M., Cherry J.D., Reisinger K.S., Blatter M.M., Congeni B.L., Dekker C.L., Stout M.G., Mezzatesta J.R., Scott J.V., Christenson P.D. Comparison of an acellular pertussis-component diptheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17-to 24-month-old children, with measurement of 69-kDa outer membrane protein antibody. J. Pediatr. 117:1990;46-51.